 |
 Video: What is a Stock Split?
|
|
|
| Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s product pipeline includes batoclimab and IMVT-1402, both of which are fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor. Co. is developing batoclimab, its first prodcut candidate, and IMVT-1402, its second product candidate, in autoimmune diseases for which there is evidence that pathogenic IgG antibodies drive disease manifestation. Co. is developing batoclimab for myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves' disease. According to our Immunovant stock split history records, Immunovant has had 0 splits. | |
|
Immunovant (IMVT) has 0 splits in our Immunovant stock split history database.
Looking at the Immunovant stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Immunovant shares, starting with a $10,000 purchase of IMVT, presented on a split-history-adjusted basis factoring in the complete Immunovant stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/24/2019 |
|
| End date: |
04/23/2024 |
|
| Start price/share: |
$9.95 |
|
| End price/share: |
$28.61 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
187.54% |
|
| Average Annual Total Return: |
24.41% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$28,753.04 |
|
| Years: |
4.84 |
|
|
|
|
|
